Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Lönngren | M | 73 | 3 years | |
| Mats Blom | M | 59 | 3 years | |
| Nicklas Westerholm | M | 48 | 7 years | |
| Lena Elisabeth Svanberg | M | 63 | 7 years | |
| Peder Sven Walberg | M | 50 | 4 years | |
| Yilmaz Mahshid | M | 45 | 3 years | |
| Karl Hård | M | 62 | 2 years | |
| Gunilla Christina Osswald | M | 63 | 7 years | |
| Peter Verwaijen | M | - | 2 years | |
| Marianne Berrens-Peijnenburg | M | - | 2 years | |
| Anna Sjögren | F | 56 | - | |
| Kristina Nygren | - | - | 3 years | |
| Christian Sonesson | M | 49 | 7 years | |
| Henrik Krook | M | 51 | 4 years | |
| Malin Nittve | F | 61 | - | |
| Katayoun Welin-Berger | M | 56 | 1 years | |
| Marie Bengtson | F | - | 13 years | |
| Mark Altmeyer | M | 63 |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | 3 years |
| Nils Hallén | M | 56 | 1 years |
See more
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 18 | 94.74% |
| Netherlands | 1 | 5.26% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Laetitia Szaller
- Personal Network
